Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.30 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22429688 | 0.85 | MEN1 (0.38) | MEN1KMT2APSMB5MTNR1AMTNR1B | |
| SCHEMBL19688544 | 0.85 | MEN1 (0.38) | MEN1KMT2APSMB5MTNR1AMTNR1B | |
| SCHEMBL22429690 | 0.85 | MEN1 (0.38) | MEN1KMT2APSMB5MTNR1AMTNR1B | |
| SCHEMBL16357807 | 0.84 | MEN1 (0.34) | MEN1KMT2APSMB5 | |
| SCHEMBL15943619 | 0.82 | MEN1 (0.44) | MEN1KMT2APSMB5MTNR1AMTNR1B | |
| SCHEMBL12719510 | 0.82 | MEN1 (0.44) | MEN1KMT2APSMB5MTNR1AMTNR1B | |
| SCHEMBL9080368 | 0.82 | MEN1 (0.44) | MEN1KMT2APSMB5MTNR1AMTNR1B | |
| SCHEMBL19661531 | 0.77 | MEN1 (0.40) | MEN1KMT2APSMB5MTNR1AMTNR1B | |
| SCHEMBL19455924 | 0.77 | MEN1 (0.40) | MEN1KMT2APSMB5MTNR1AMTNR1B | |
| SCHEMBL22430007 | 0.77 | KDM4E (0.52) | MEN1KMT2APSMB5MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20170348376-A1 | TUBULYSIN CONJUGATE FOR USE IN TREATING CANCER | ENDOCYTE, INC. | 2017-12-07 | — | — | US | disclosed |
| WO-2017205661-A1 | METHOD OF TREATING CANCER BY TARGETING MYELOID-DERIVED SUPPRESSOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2009002993-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | MEN1 186/4885KMT2A 961/4885PSMB5 1032/4885 |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | MEN1 186/4885KMT2A 961/4885PSMB5 1032/4885 |
| US-20170348376-A1 | TUBULYSIN CONJUGATE FOR USE IN TREATING CANCER | FOLH1, FOLR1, FOLR2 | MEN1 513/4885KMT2A 1877/4885PSMB5 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.